Nasus Pharma, Ltd.

Contributing Author

Recent Articles by Nasus Pharma, Ltd.

Feb-10	Nasus Pharma Announces Pricing of $15.0 Million Private Placement NSRX GlobeNewswire
Jan-20	Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder NSRX -7.52% GlobeNewswire
Dec-22	Nasus Pharma CEO Issues 2025 Letter to Shareholders NSRX -6.56% GlobeNewswire
Nov-20	Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer NSRX GlobeNewswire
Nov-18	Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed NSRX GlobeNewswire
Nov-06	Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder NSRX GlobeNewswire
Sep-02	Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference NSRX GlobeNewswire
Aug-26	Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony NSRX GlobeNewswire
Aug-14	Nasus Pharma Announces Closing of Initial Public Offering NSRX GlobeNewswire